Literature DB >> 7534702

Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat.

J A Lugg1, J Rajfer, N F González-Cadavid.   

Abstract

Androgens are essential for the expression of normal libido in the male, but their role in the maintenance of the erectile response in humans is controversial. It has been shown previously in the rat that castration induces 1) loss of penile reflexes; and 2) considerable reduction in the erectile response to electric field stimulation (EFS) of the cavernosal nerve. Both of these effects can be reversed by testosterone replacement. The current study was performed to determine whether these testosterone effects are mediated via its conversion to dihydrotestosterone (DHT), and to what extent the synthesis of the mediator of penile erection, nitric oxide, is affected by castration and androgen replacement. Five-month-old rats were either castrated or left intact. The orchiectomized rats were implanted with SILASTIC brand silicon tubing (Dow Corning) containing testosterone or DHT with or without daily injections of the 5 alpha-reductase inhibitor finasteride. After 7 days, rats were submitted to EFS and the intracavernosal pressure was recorded. Castration reduced the EFS-induced erectile response by 50% in comparison with intact rats and testosterone restored this decrease to normal. When finasteride was given to these testosterone-treated castrate rats, erectile response was not restored. DHT was as effective as testosterone in restoring response to EFS in castrates and this effect was not decreased by finasteride. Nitric oxide synthase activity in the penile cytosol was measured by the arginine-citrulline conversion and was found to correlate with the EFS determinations. These results show that DHT is the active androgen in the prevention of erectile failure seen in castrated rats, and suggest that this effect may be mediated, at least partially, by changes in nitric oxide synthase levels in the penis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534702     DOI: 10.1210/endo.136.4.7534702

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  33 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 2.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 3.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

Review 4.  Varicocele and hypogonadism.

Authors:  Ali Dabaja; Matthew Wosnitzer; Marc Goldstein
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

Review 5.  Rise of herbal and traditional medicine in erectile dysfunction management.

Authors:  Christopher C K Ho; Hui Meng Tan
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 6.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

Review 7.  Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction.

Authors:  Carol A Podlasek; John Mulhall; Kelvin Davies; Christopher J Wingard; Johanna L Hannan; Trinity J Bivalacqua; Biljana Musicki; Mohit Khera; Nestor F González-Cadavid; Arthur L Burnett
Journal:  J Sex Med       Date:  2016-08       Impact factor: 3.802

8.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 9.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

Review 10.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.